Explore where VETS has led, supported, or influenced legislation, funding, research programs, and access infrastructure across the country. Select a highlighted state to filter the policy portfolio below.
Click a highlighted state to view its policy records.
Search and filter VETS' policy records by state, year, role, status, and research focus. Select any record to view full details.
Built on the state-level policy infrastructure VETS helped establish, especially Texas HB 1802, Texas SB 2308, and related state programs.
Builds directly on the 2025 Georgia appropriation and the Douglas Mike Day Act funding.
Appropriation effort planned for 2027. Companion to Texas SB 2308. Part of consortium with Texas, West Virginia, Missouri, Tennessee, and Mississippi.
HMHI has elected to pursue 5-MeO-DMT research. Matching philanthropic funds of up to $2M to be awarded by HMHI donors.
Funding contingent on gifts, grants, and donations. Allows up to five sites to establish research and treatment programs.
Part of the growing multi-state ibogaine research consortium catalyzed by SB 2308.
Includes a veteran-focused ibogaine/PAT pilot and a separate psilocybin research pilot. Influenced by Texas SB 2308 and HB 1802.
Requires institutions to pursue FDA approval, provide matching funds, and report progress and safety outcomes. Influenced by Texas SB 2308.
Part of the growing multi-state ibogaine research consortium catalyzed by SB 2308.
Builds on AB 2841. Establishes expedited review process and extends open-meeting exemptions for researchers.
First Georgia veteran dosed with state-funded MDMA in March 2026. Builds from the Douglas Mike Day Act trial.
Three $2M grants to in-state hospital systems. Institutions to be publicly announced upon contract execution.
Initial $50M appropriation increased to $100M in 2026. First public funding for ibogaine research anywhere in the world. Influenced companion legislation in 12+ states, with 7 passed into law.
Two $5M grants. RFP underway; no institutions publicly announced. Builds on Arizona SB 1726 from 2023.
Aligns Illinois regulatory decisions with FDA approval and DEA rescheduling to support immediate access upon federal approval.
Allows prescribing, dispensing, and use upon FDA approval and DEA rescheduling.
Allows prescribing, dispensing, and use of crystalline polymorph psilocybin upon FDA approval and DEA rescheduling.
Allows prescribing, dispensing, and use of crystalline polymorph psilocybin upon FDA approval and DEA rescheduling.
Allows prescribing, dispensing, and use of crystalline polymorph psilocybin upon FDA approval and DEA rescheduling.
Authorized RAPC closed-session meetings to review sensitive research, protecting IP and trade secrets. Established a precedent for procedural reform beyond appropriations.
Directed to make recommendations to the Governor and Legislature. Influenced by Texas HB 1802.
Expanded the HB 167 task force framework into direct treatment authorization. Influenced by Texas HB 1802 and Utah HB 167.
Authorized two $5M grants: one to UT Health San Antonio & Emory University, and one to Walter Reed. Includes MDMA + Prolonged Exposure Therapy trial and active-duty clinical research.
Funded Phase 1, 2, and 3 clinical trials for PTSD, depression, and anxiety. Created Arizona's Psilocybin Research Advisory Council as a permanent body.
Working group published a report creating a framework for expanded access and research in Nevada.
Contracting was delayed; funds were reappropriated in FY2026 and contracting is now underway.
Recommendations paved the way for expanded FDA clinical research in Utah and later implementation efforts, including Utah SB 266 and HB 390.
First Texas veteran dosed with state-funded psilocybin in January 2026; expected conclusion Q4 2026. Cited as a model in Nevada, Utah, Arizona, Illinois, Maryland, and beyond. Helped catalyze the McGill Center at UT Austin Dell Medical School.
No policy records match those filters yet. to see the full portfolio.
Key terms used throughout this dashboard, defined for clarity and transparency.
Your support fuels the advocacy, research, and coalition building that makes these policy victories possible.
We encourage anyone seeking help to contact our partners at the Suicide Prevention Lifeline or the Veterans Crisis Line.
